Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
Publishing timestamp: 2024-05-21 13:47:58
Summary
Eli Lilly and Novo Nordisk are in a race to develop once-weekly insulin injections for diabetes patients. Eli Lilly's efsitora showed positive initial data in late-stage clinical trials, but is slightly behind Novo Nordisk's icodec. Meanwhile, Uber announced a new feature called Uber Caregiver to help individuals support their loved ones by allowing caregivers to book rides and order supplies on their behalf.
Sentiment: NEUTRAL
Tickers: UBER, NOVO.B-DK, LLY,
Keywords: science, uber technologies inc, eli lilly and co, health care industry, business news, biotech and pharmaceuticals, novo nordisk a/s,
Source: https://www.cnbc.com/2024/05/21/healthy-returns-eli-lilly-novo-nordisk-develop-weekly-insulin.html